RICHMOND, Va. - A whistle-blower whose False Claims Act (FCA) 31 U.S.C.S. § 3729-3733 complaint resulted in a $42.5 million settlement by Alpharma Inc. failed to prove that she was fired in retaliation for telling the company about possible FCA violations in connection with the promotion of a controlled-release morphine drug, a Fourth Circuit U.S. Court of Appeals panel held Aug. 14 (United States of America, ex rel. Debra Parks v. Alpharma, Incorporated, et al., No. 11-1498, 4th Cir.; 2012 U.S. App. LEXIS 17155).